Ryan Jacobs Email & Phone Number

San Diego, Ca, Us

Milwaukee, Wi, Us

Helping customers streamline cell and gene therapy manufacturing processes and workflows utilizing pre-validated automated, scalable solutions.

Jena, Thüringen, De

• ZEISS RMS Business Development Manager for biotech and pharma in North America. Supporting sales and marketing initiatives across all light microscopy platforms, as well as correlative workflows involving X-Ray and electron microscopy.

Portland, Oregon, Us

• Responsible for sales and marketing of Endeavor high-content analysis platform.• Involved in various business development related activities.

San Jose, Ca, Us

• Responsible for sales and marketing in Biopharma-South Territory (20 states) supporting the ClonePix, Qpix, and CloneSelect platforms. Based out of San Diego, CA.

Winooski, Vermont, Us

• Technical representative for the sales and marketing of capital equipment in the western Pennsylvania, western New York, and West Virginia territories. Based out of Pittsburgh, PA.• Instrumentation and control/analysis software expertise involving robotic automation, liquid handling, microplate washing/dispensing, multi-mode detection (microplate readers), cellular imaging/live cell analysis, automated microscopy, and automated cell culture incubation.

Raritan, New Jersey, Us

• Participated in discovery research involving targeted therapeutics and local delivery of antibody-drug/ASO conjugates and nano-particles.• Involved in project to select antibody-ASO conjugate and treatment titer for solid tumor CRC mouse study via oral administration – target goal leading to subsequent mixed therapy treatment study.• Assessing various antibody-ASO conjugates in-vitro (single and mixed cell cultures) for Antibody Kint, ASO knockdown, and phenotypic cellular proliferation response.• Supported cellular response study to engineered bovine milk exosome-drug payload treatment.

Summit, New Jersey, Us

• Member of Celgene protein homeostasis team tasked with screening and identifying targeted E3 ligase substrates via specific drug library treatments and developing cellular response models using traditional in-vitro assays, a variety of in-group developed in-cell systems, and mass spec analysis via proteomic workflows.• Developed a cellular bimolecular fluorescence complementation assay (BiFC) used to view drug mediated E3 ligase/substrate binding in-cell. Required extensive lentiviral transfection, cell line selection and testing vector constructs for assay development and optimization.• Developed magnetic bead based co-immunoprecipitation assay to identify drug mediated binding of recombinant E3 ligase and target substrates via western blot analysis following in-vivo compound treatment. Utilized lateral flow kits to identify recombinant substrate expression in transfected cell lines.• Transitioned bead based co-immunoprecipitation into plate based ELISA for direct quantitation and high-throughput. Immunoassay is used to validate target substrates from BiFC complementation assay in-vitro, as well as assess recombinant substrates that were unable to work and/or express properly within cellular BiFC system.• Validated a mathematically predicted cellular model to assess novel apoptotic pathway initiated by acute myeloid leukemia (AML) drug treatment in phase I clinical trials. Employed a variety of drug dose response and ligand timecourse treatments to view signaling marker modulations in AML cell lines utilizing western blot, RNA, and proteomic analysis.• Involved in multi-group study responsible for selecting solid tumor drug for clinical candidacy via targeted E3 ligase substrate degradation. Screened multiple compound libraries against solid tumor cell line panel to assess cell viability and identify cellular toxicity, phenotypic sensitivity, and subsequent analysis of specific targets/downstream markers using proteomics and RNA analysis.

San Diego, Ca, Us

• Participated in development of industry leading 96-sample DNA microarray platform/workflow with multi-species screening capabilities known as Infinium XT (aka “Dragonfish” – Illumina BeadArray technology) in the Applied Genomics Development Department.• Daily/weekly meetings with R&D team to target optimization/problematic phenotypic issues of entire Infinium XT workflow via biochemical assay development, review data, and assess subsequent testing.• Collaborated with senior R&D engineers to design, implement, test, revise (multiple prototypes), and verify in-house developed, Illumina specific accessory devices for Tecan EVO liquid handling systems necessary for Infinium XT automated workflows.• Consistently involved with software engineering team to develop, test and verify liquid handling workflow scripts for Infinium XT workflow. Worked in-conjunction with assay development team to properly implement, test, and optimize microarray chemistry to automated workflow. Experimental results and analysis critical in updating proprietary Illumina Automation Control software (IAC) for Infinium XT automated workflows.• Supported software engineering team in development/update/verification of Illumina LIMS software as it pertains to Infinium XT workflows, with additional goal to prepare LIMS software for future clinical use.• Worked with project lead to write and revise design verification testing (assay DVT) protocol for Infinium XT automated workflows: standard throughput (ST), high throughput (HT), and ultra-high throughput (UHT). Performed verification testing, documentation, and data review with assay team.• Individually designed, submitted, and executed hardware and software engineering experiments (DOEs); subsequent peer-reviewed analysis of experimental results. Wrote and submitted official engineering reports for all work, testing, and analysis performed.

• Critical in immunoassay development of ELISA-based workflow, which formed the basis of company ability to reliably and reproducibly quantify human plasma colorectal cancer/advanced adenoma biomarkers.• Crucial in implementing and training other research associates in automation to ELISA-based and targeted proteomic workflows, increasing company data throughput several fold.• Optimized ELISA assays for automated system scalability and commercial clinical testing. • Participated in immunoassay product development of proprietary ELISAs and targeted mass spec assays (via SISCAPA technology) used for clinical LDT.• Led the development, preparation, and execution of large (1500+ sample cohort) ELISA-based studies, the data from which was directly utilized for creating the classifier resulting in SimpliPro Colon LDT product launched in December 2015.• Essential to the planning and execution of large (1500+ sample cohort) mass-spectrometry based proteomic workflows on human plasma biomarkers used to verify current product classifier and to develop/improve future products. Performed entirety of mass spec workflow: sample prep/filtration, HPLC immuno-depletion, buffer exchange & dry down, TPA calculation, digestion & dry down, peptide re-suspension, MS injection.• Responsible for individual DOE, testing, analysis, and submission of ELISA kit characterization experiments to assess validity, robustness, and application of kit assay for larger research study and eventual development for ELISA-based workflow.• Tasked with learning, utilizing, and helping to develop/optimize clinical LIMS software with in-house software engineers for documenting research, clinical samples, and results.• Wrote and reviewed SOPs, instrumentation upkeep, repair, and documentation.

Philadelphia, Pa, Us

Principle Investigator: Greg H. Enders, MD, PhDPostdoctoral Fellow: Sanjeevani Arora, PhD• Supported several projects under the direction of post-doctoral fellow and principle investigator, utilizing numerous wet lab techniques: PCR, DNA/RNA isolation and purification, southern blot, protein enrichment and quantification, western blot, ELISA, magnetic/latex bead based immunoprecipitation, immunofluorescence labeling, immunohistochemistry, histology imaging.• Performed individual research project studying CDK and mitotic regulation by nuclear protein kinase Wee1 to help improve molecular model of mitotic entry and associated Wee1 regulatory/cell cycle functions. • Experience with mammalian cell culture and aseptic techniques, bacterial transfection and plasmid amplification/purification (Mini/Midiprep).• Kept detailed notebook on laboratory procedures and results. Weekly meetings with principle investigator and post-doctoral fellow to discuss experimental results and research direction.• Initially volunteered and then employed full-time as research assistant while completing graduate courses at Penn State-Abington campus.

Rahway, New Jersey, Us

• Successfully developed and tested pilot screening studies; helped to develop and optimize cell based high-throughput screening assays in team-based industry setting; executed follow-up dose response studies.• Involved in planning and execution of compound management schedule to meet several research project needs: cherry picking custom libraries, whole library replication, dose response plates, etc.• Engaged in process development to upscale HTS source plates from 1536 to 3456-well plates. Involved expansion of entire compound management workflow to accommodate increased output, as well as verification and peer-review of project design. Implemented 3456 HTS source plates with Biosero ATS acoustic dispensing platform to increase throughput for all screening studies thereafter.• Updated compound management dose response workflow to increase throughput: expanded 96-well dose response serial dilutions into 384-well plates; sequential transfer into1536-well source plates using 96-well head. Drastically increased dose response throughput while simultaneously decreasing compound management consumables used by several fold.• Utilized numerous automated robotic systems, support platforms, and control software; wrote and edited automated run-procedures; troubleshoot all associated instruments/systems.• Followed SOPs and cGLP; wrote and reviewed SOPs for various automated systems and processes.• Individually trained and oversaw two contract research technicians.

Farmingdale, Ny, Us

Formerly BIOMOL International• Routinely assisted with synthesis, QC analysis, and upkeep within chemistry department.• Performed chemical breakdowns, recrystallizations, lyophilisations, etc.• Experience preparing various product solutions and specialized packaging of biochemical and organic compounds.• Managed cyclic inventory and product stock within company databases.• Followed SOPs for work performed; adhered to cGLP.

Bachelor'S Degree, Cell Biology/Biochemistry

Hs Diploma, Physics/Chemistry